Martin Madaus, president and chief executive officer of Roche Diagnostics, will join Millipore of Billerica, Mass., as president and chief executive officer in February, the company said this week. He replaces Francis Lunger, who will remain chairman of the board of Millipore in a transition period. Madaus, 45, who led Roche Diagnostics since 2000, will also join Millipore’s board. Madaus previously was president of business development for Roche Diagnostics, a position he took when Roche acquired Boehringer Mannheim, where he was general manager of the company’s Canadian business. Heino von Prondzynski, the head of Roche’s worldwide diagnostics business, based in Basel, Switzerland, will take over Madaus’ role as the company seeks a replacement, Roche said.
The Burnham Institute last week announced that Douglas Obenshain has been elected to its board of trustees. Obenshain is a partner with Ernst & Young, where his practice focuses primarily on biotechnology, pharmaceutical, and medical device companies, the institute said.
Richard Riegel has joined life science consulting firm Taratec as vice president of sales and business development. Riegel comes to Taratec from IBM, where he served most recently as vice president of solutions marketing for IBM Healthcare and Life Sciences and previously as general manager of the company’s Pharmaceutical Industry practice. Prior to joining IBM, Riegel spent eight years at First Consulting Group in a number of positions, including managing director of the company’s Life Sciences Division.
Kurt Vedder joined the venture capital firm De Novo Ventures of Menlo Park, Calif., as director of strategic business development and research, the company said last week. Previously, Vedder was a business development manager for Guidant and Medtronic. De Novo invests in early-stage life-science technology and medical device companies.
Â